Clinical Research Directory

Inclusion Criteria: * Squamous cell or adenocarcinoma of the cervix * At least one prior chemotherapy regimen for recurrent or advanced disease with a platinum-taxane combination, but not more than two lines of chemotherapy or targeted therapy in recurrent/advanced setting * Measurable disease * ECOG≤2 * Adequate pretreatment hematologic, renal and hepatic function test * Patients are allowed to have had bevacizumab during their prior treatment * Evidence of non-childbearing status for women of childbearing potential Exclusion Criteria: * History of invasive malignancy other than cervical cancer unless there is no recurrence of these other primary tumors the last 3 years. * Previous anthracycline-based chemotherapy * Central nerve system metastases and leptomeningeal disease * Active or history of autoimmune disease * Prior allogenic bone marrow transplantation or prior solid organ transplantation * History of idiopathic pulmonary fibrosis * Known positive test for HIV, or active hepatitis B or hepatitis C * Known active tuberculosis * Severe infection within 4 weeks prior to initiation of study treatment * Prior immunotherapy